The U.S. Food and Drug Administration (FDA) approved Twyneo for use in the treatment of acne vulgaris on July 26, 2021.

The U.S. Food and Drug Administration (FDA) approved belumosudil on July 16, 2021.

The U.S. Food and Drug Administration (FDA) approved finerenone on July 9, 2021.

Aducanumab, sold under the brand name Aduhelm, is an intravenous medication used to treat Alzheimer's disease. Aducanumab was approved by the U.S. Food and Drug Administration (FDA) on June 7, 2021.

Ryplazim was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021. This approval marked a significant milestone as Ryplazim is the first therapy approved for treating plasminogen deficiency type 1.

Tembexa (brincidofovir) was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021.

Brexafemme (ibrexafungerp) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021.

Lybalvi, a combination of olanzapine and samidorphan, is an antipsychotic medication designed to treat specific mental health conditions in adults. Lybalvi was approved by the U.S. Food and Drug Administration (FDA) on May 28, 2021.

Sotorasib, marketed under the brand name Lumakras, is a medication designed to treat non-small cell lung cancer (NSCLC). Sotorasib was granted FDA approval on May 28, 2021.

Myfembree is a combination oral medication containing estradiol, norethindrone, and relugolix. Myfembree was approved by the FDA on May 26, 2021.

Pylarify was approved by the U.S. Food and Drug Administration (FDA) on May 26, 2021.

The U.S. Food and Drug Administration (FDA) approved amivantamab (Rybrevant) on May 21, 2021.